for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amneal Pharmaceuticals Inc

AMRX.N

Latest Trade

3.16USD

Change

0.16(+5.33%)

Volume

130,574

Today's Range

3.00

 - 

3.22

52 Week Range

2.27

 - 

14.65

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Amneal Accelerates Production Of Hydroxychloroquine Sulfate

March 20 (Reuters) - Amneal Pharmaceuticals Inc <AMRX.N>::AMNEAL ACCELERATES DISTRIBUTION AND PRODUCTION OF HYDROXYCHLOROQUINE SULFATE TO MEET POTENTIAL NEEDS OF COVID-19 PATIENTS NATIONWIDE.AMNEAL PHARMACEUTICALS - RAMPING UP PRODUCTION OF HYDROXYCHLOROQUINE SULFATE & EXPECTS TO PRODUCE ABOUT 20 MILLION TABLETS BETWEEN NOW & MID-APRIL.AMNEAL PHARMA - CO'S HYDROXYCHLOROQUINE SULFATE TABLETS APPROVED BY FDA TO TREAT MALARIA, RHEUMATOID ARTHRITIS, LUPUS, CHILDHOOD ARTHRITIS, OTHERS.

Amneal Reports Q4 Adj. Earnings Per Share Of $0.08

Feb 26 (Reuters) - Amneal Pharmaceuticals Inc <AMRX.N>::AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS.Q4 ADJUSTED EARNINGS PER SHARE $0.08.Q4 REVENUE $397 MILLION VERSUS REFINITIV IBES ESTIMATE OF $394.8 MILLION.Q4 LOSS PER SHARE $0.23.Q4 EARNINGS PER SHARE ESTIMATE $0.05 -- REFINITIV IBES DATA.SEES 2020 NET REVENUE BETWEEN $1,875 MILLION TO $1,975 MILLION.FY2020 REVENUE VIEW $1.70 BILLION -- REFINITIV IBES DATA.SEES 2020 ADJUSTED EPS $0.45 - $0.60.

Amneal Receives Abbreviated New Drug Application Approval For Eluryng, The First Generic Nuvaring

Dec 12 (Reuters) - Amneal Pharmaceuticals Inc <AMRX.N>::AMNEAL RECEIVES ABBREVIATED NEW DRUG APPLICATION APPROVAL FOR ELURYNG™, THE FIRST GENERIC NUVARING®.AMNEAL PHARMACEUTICALS INC - HAS INITIATED COMMERCIALIZATION ACTIVITIES FOR ELURYNG.AMNEAL PHARMACEUTICALS - ANNOUNCES FDA APPROVAL OF ELURYNG, ONE OF 15 NEW PRODUCTS CO EXPECTS TO LAUNCH OVER NEXT 18 TO 24 MONTHS.

Amneal To Acquire Majority Interest In AvKARE, Enhancing Access To Growing Federal Healthcare Market

Dec 10 (Reuters) - Amneal Pharmaceuticals Inc <AMRX.N>::AMNEAL TO ACQUIRE MAJORITY INTEREST IN AVKARE, ENHANCING ACCESS TO GROWING FEDERAL HEALTHCARE MARKET.AMNEAL PHARMACEUTICALS INC - DEAL FOR IMPLIED ENTERPRISE VALUE OF $340 MILLION.AMNEAL PHARMACEUTICALS INC - FOLLOWING CLOSE OF TRANSACTION, AVKARE WILL OPERATE ON A STANDALONE BASIS AS AN INDEPENDENT SUBSIDIARY OF AMNEAL.AMNEAL PHARMACEUTICALS INC - AMNEAL WILL ACQUIRE A 65.1% MAJORITY INTEREST IN AVKARE.AMNEAL PHARMACEUTICALS - CONTRIBUTED ROLLOVER INTEREST WILL BE RETAINED BY SHIRLEY FAMILY, AVKARE'S FOUNDERS.AMNEAL PHARMACEUTICALS - SHIRLEY FAMILY WILL CONTINUE TO INDEPENDENTLY MANAGE OPERATIONS OF BUSINESS.AMNEAL PHARMACEUTICALS - CO TO PARTLY FINANCE PURCHASE OF AVKARE WITH A NEW $180 MILLION SENIOR SECURED TERM LOAN FACILITY.AMNEAL PHARMACEUTICALS - NEW DEBT FINANCING WILL BE SECURED BY NEWLY FORMED UNRESTRICTED SUBSIDIARY & WILL NOT IMPACT CO'S EXISTING TERM LOAN FACILITY.AMNEAL PHARMACEUTICALS INC - FOR TWELVE-MONTH PERIOD ENDED OCTOBER 31, 2019, AVKARE'S UNAUDITED CONSOLIDATED EBITDA WAS APPROXIMATELY $63 MILLION.AMNEAL PHARMACEUTICALS - ON A CONSOLIDATED BASIS, TRANSACTION IS EXPECTED TO REDUCE CO'S NET DEBT TO ADJUSTED EBITDA LEVERAGE RATIO.

Amneal Pharmaceuticals Announces Approval And Launch Of Generic Carafate

Dec 3 (Reuters) - Amneal Pharmaceuticals Inc <AMRX.N>::AMNEAL ANNOUNCES APPROVAL AND LAUNCH OF GENERIC CARAFATE.AMNEAL PHARMACEUTICALS INC - INITIATED GENERIC CARAFATE COMMERCIALIZATION ACTIVITIES..

Amneal Announces Approval And Launch Of Generic Revatio For Oral Suspension And Generic Amicar Tablets

Dec 2 (Reuters) - Amneal Pharmaceuticals Inc <AMRX.N>::AMNEAL ANNOUNCES THE APPROVAL AND LAUNCH OF GENERIC REVATIO® FOR ORAL SUSPENSION AND GENERIC AMICAR® TABLETS.AMNEAL PHARMACEUTICALS - RECEIVED FINAL U.S. FDA APPROVAL ON ITS ABBREVIATED NEW DRUG APPLICATIONS FOR GENERIC VERSIONS OF REVATIO.AMNEAL PHARMACEUTICALS INC - HAS IMMEDIATELY INITIATED COMMERCIALIZATION ACTIVITIES.

Amneal Enters Into A Licensing Agreement With Kashiv Biosciences, Llc To Develop And Commercialize K127 For The Treatment Of Myasthenia Gravis

Amneal Pharmaceuticals Inc <AMRX.N>::AMNEAL ENTERS INTO A LICENSING AGREEMENT WITH KASHIV BIOSCIENCES, LLC TO DEVELOP AND COMMERCIALIZE K127 FOR THE TREATMENT OF MYASTHENIA GRAVIS.AMNEAL PHARMACEUTICALS INC - AMNEAL GAINS EXCLUSIVE RIGHTS WITHIN UNITED STATES TO NEW DRUG APPLICATION (NDA) AND COMMERCIALIZATION OF K127.AMNEAL PHARMACEUTICALS - UNDER TERMS KASHIV WILL BE RESPONSIBLE FOR ALL DEVELOPMENT, CLINICAL WORK REQUIRED TO SECURE FDA APPROVAL.AMNEAL PHARMACEUTICALS - KASHIV WILL RECEIVE UPFRONT PAYMENT OF $1.5 MILLION & IS ELIGIBLE TO RECEIVE DEVELOPMENT & REGULATORY MILESTONES OF $16.5 MILLION.

Amneal Announces Launch Of Generic Invega

Oct 10 (Reuters) - Amneal Pharmaceuticals Inc <AMRX.N>::AMNEAL ANNOUNCES LAUNCH OF GENERIC INVEGA®.AMNEAL PHARMACEUTICALS INC - HAS LAUNCHED ITS GENERIC VERSION OF INVEGA (PALIPERIDONE) EXTENDED-RELEASE TABLETS, 1.5 MG, 3 MG, 6 MG, AND 9 MG.

Amneal Announces Approval Of Generic Version Of Amicar

Sept 5 (Reuters) - Amneal Pharmaceuticals Inc <AMRX.N>::AMNEAL ANNOUNCES APPROVAL OF GENERIC VERSION OF AMICAR®.AMNEAL PHARMACEUTICALS INC - COMPANY GRANTED 180 DAYS OF EXCLUSIVITY UNDER FDA COMPETITIVE GENERIC THERAPY APPROVAL PATHWAY.AMNEAL PHARMACEUTICALS INC - RECEIVED APPROVAL FROM U.S. FDA FOR GENERIC VERSION OF AMICAR (AMINOCAPROIC ACID ORAL SOLUTION) 0.25G/ML..

Amneal Pharmaceuticals Q2 Adjusted Earnings Per Share $0.09

Amneal Pharmaceuticals Inc <AMRX.N>::AMNEAL REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 REVENUE $405 MILLION VERSUS REFINITIV IBES ESTIMATE OF $428.6 MILLION.Q2 ADJUSTED EARNINGS PER SHARE $0.09.Q2 GAAP LOSS PER SHARE $0.13.Q2 EARNINGS PER SHARE ESTIMATE $0.14 -- REFINITIV IBES DATA.REAFFIRMS FULL YEAR 2019 EBITDA GUIDANCE.SEES FY 2019 ADJUSTED DILUTED EPS $0.52 - $0.62.SEES FY 2019 CAPITAL EXPENDITURES $65 MILLION - $85 MILLION.FY2019 EARNINGS PER SHARE VIEW $0.61 -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up